118 related articles for article (PubMed ID: 38450972)
1. Development and characterization of a cell donor registry for virus-specific T cell manufacture in a blood bank.
Rudilla F; Carrasco-Benso MP; Pasamar H; López-Montañés M; Andrés-Rozas M; Tomás-Marín M; Company D; Moya C; Larrea L; Guerreiro M; Barba P; Arbona C; Querol S
HLA; 2024 Mar; 103(3):e15419. PubMed ID: 38450972
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
3. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
4. A cost-effective strategy for selection of third-party donors for a virus-specific T-cell bank for an Asian patient population.
Linn YC; Sundar Raj K; Teo B; Phang CY; Chittezhath M; Koh M
Cytotherapy; 2023 May; 25(5):510-520. PubMed ID: 36882347
[TBL] [Abstract][Full Text] [Related]
5. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
6. Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry.
Eiz-Vesper B; Maecker-Kolhoff B; Blasczyk R
Front Immunol; 2012; 3():410. PubMed ID: 23372567
[TBL] [Abstract][Full Text] [Related]
7. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
8. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
9. A registry of HLA-typed donors for production of virus-specific CD4 and CD8 T lymphocytes for adoptive reconstitution of immune-compromised patients.
Li Pira G; Ivaldi F; Starc N; Landi F; Rutella S; Locatelli F; Sacchi N; Tripodi G; Manca F
Transfusion; 2014 Dec; 54(12):3145-54. PubMed ID: 25041366
[TBL] [Abstract][Full Text] [Related]
10. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
11. Distributions of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 alleles and haplotype frequencies of 1763 stem cell donors in the Colombian Bone Marrow Registry typed by next-generation sequencing.
Hernández-Mejía DG; Páez-Gutiérrez IA; Dorsant Ardón V; Camacho Ramírez N; Mosquera M; Cendales PA; Camacho BA
Front Immunol; 2022; 13():1057657. PubMed ID: 36700199
[TBL] [Abstract][Full Text] [Related]
12. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
[TBL] [Abstract][Full Text] [Related]
13. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
14. Availability of HLA-allele-matched unrelated donors and registry size: Estimation from haplotype frequency in the Italian population.
Sacchi N; Ciceri F; Bonifazi F; Algeri M; Gallina A; Pollichieni S; Raggio E; Hadj-Amar B; Lombardini L; Pupella S; Liumbruno G; Cardillo M
Hum Immunol; 2021 Oct; 82(10):758-766. PubMed ID: 34353675
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of human EBV- and CMV-specific cytolytic effector function using allogeneic HLA molecules.
D'Orsogna LJ; van den Heuvel H; van der Meer-Prins EM; Roelen DL; Doxiadis II; Claas FH
J Immunol; 2012 Nov; 189(10):4825-31. PubMed ID: 23077240
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of CMV, EBV, and adenovirus tissue infection following HLA-mismatched allogeneic stem cell transplant using infusion of third-party T cells from multiple donors in addition to antivirals, rituximab, and surgery.
Di Ciaccio PR; Avdic S; Sutrave G; Clancy L; Withers B; Blyth E; McLeod D; Gottlieb DJ
Transpl Infect Dis; 2021 Apr; 23(2):e13528. PubMed ID: 33236399
[TBL] [Abstract][Full Text] [Related]
17. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
[TBL] [Abstract][Full Text] [Related]
18. HLA-DR-restricted cytotoxicity of cytomegalovirus-infected monocytes mediated by Leu-3-positive T cells.
Lindsley MD; Torpey DJ; Rinaldo CR
J Immunol; 1986 Apr; 136(8):3045-51. PubMed ID: 2420881
[TBL] [Abstract][Full Text] [Related]
19. Recruiting refugees and migrants as potential hematopoietic stem cell donors to serve patients of comparable ethnicities with rare human leucocyte antigen patterns - The BluStar.NRW project in North Western Germany.
Heinemann FM; Baumgart C; Binder C; Börger V; Fischer JC; Heinold A; Jiménez Klingberg C; Lenz V; Riebschläger S; Zeiler T; Horn PA; Kordelas L
Transpl Immunol; 2024 Feb; 82():101985. PubMed ID: 38184211
[TBL] [Abstract][Full Text] [Related]
20. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
